

Aestus Therapeutics and Prosidion Ltd Sign License Agreement for Novel Chronic Pain Therapeutic

East Windsor, NJ and Oxford, UK – September 19, 2010 – Aestus Therapeutics, Inc. and Prosidion Ltd., a wholly owned subsidiary of Astellas Pharma Inc., announced today a license agreement providing Aestus with exclusive, world-wide rights to the Prosidion investigational product PSN-357. Aestus will develop the product as ATx09-002, a novel, first-in-class therapeutic for the treatment of neuropathic pain.

Using their proprietary, systems biology engine for the analysis of genome-scale expression data, and animal models accepted to be good indicators for neuropathic pain in patients, Aestus identified ATx09-002, a glycogen phosphorylase inhibitor, as a potential therapeutic for the treatment of neuropathic pain. ATx09-002 has an excellent safety and toxicology profile demonstrated during Phase I and II studies conducted by Prosidion.

“We are pleased to enter into this licensing agreement with Prosidion which we believe is a valuable addition to our pain portfolio,” stated Tage Honore, Ph.D., DSc, CEO and co-founder of Aestus. “We are optimistic that this compound will eventually provide much needed treatment options to help those who suffer from chronic pain.”

Aestus will evaluate the efficacy of ATx09-002 in Phase II clinical trials for post-herpetic neuralgia (PHN), the persistent neuropathic pain following an outbreak of shingles. According to the National Institutes of Health, more than one million new cases of shingles are reported each year in the United States, nearly half of which will lead to PHN. Neuropathic pain is also a common complication of cancer, diabetes, viral infections, and other diseases. There is no effective treatment to relieve neuropathic pain which is poorly managed by current drugs and affects an estimated 39 million sufferers globally.

Pierre Legault, President and Chief Executive Officer of Prosidion Ltd., commented, “This agreement with Aestus fits well with Prosidion’s strategy as we seek to maximize the potential of compounds we have discovered and contribute to the development of much needed therapies either by Prosidion or by our partners. We are delighted that Aestus has identified the potential for PSN-357 to bring relief to neuropathic pain sufferers worldwide.”

Aestus has recently completed a placebo controlled, double blind, clinical Phase II study in post-herpetic neuralgia of its lead compound ATx08-001. Aestus expects to provide an update on the results of this study later this year.

About Aestus Therapeutics, Inc.

Aestus Therapeutics, Inc. is a translational medicine company focused on serious neurological diseases. Capitalizing on genomic data analysis to discover novel links between these diseases and well-studied biological pathways, Aestus identifies drug candidates in clinical Phase I or later. By developing these drugs in novel disease areas such as chronic pain, ALS, schizophrenia and epilepsy, Aestus greatly reduces the time, cost and risk required to deliver better and safer medicines for the benefit of patients and society. www.aestustherapeutics.com

About Prosidion Ltd.

Prosidion Ltd. (a wholly owned subsidiary of Astellas Pharma Inc.) is a biopharmaceutical company, focused on discovering, developing and commercializing innovative molecular targeted therapies addressing major unmet medical needs in type 2 diabetes and obesity. The company’s biological research is focused on neuroendocrine control of body weight and glycemia. This combined with special expertise in the area of designed multiple ligands is geared to deliver novel, innovative first – or best-in-class therapies for type 2 diabetes and obesity. Prosidion is located in Oxford, in the UK close to a seat of international academic excellence. The company has state of the art facilities and fully integrated capabilities in research and development. <http://www.prosidion.com>

Statement of Cautionary Factors

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage.

Media Contacts:

Lisa McCormick, Aestus Therapeutics, 609-865-4014, lmccormick@aestustherapeutics.com
Stewart Sharpe, Prosidion Ltd, +44 (0)1865 782600, ssharpe@prosidion.com

#